The economic burden of vertigo and dizziness in the United States

被引:33
|
作者
Ruthberg, Jeremy S. [1 ]
Rasendran, Chandruganesh [1 ]
Kocharyan, Armine [2 ]
Mowry, Sarah E. [1 ,2 ]
Otteson, Todd D. [1 ,2 ]
机构
[1] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[2] Univ Hosp Cleveland, Dept Otolaryngol Head & Neck Surg, Med Ctr, Cleveland, OH 44106 USA
关键词
Otolaryngology; vertigo; dizziness; economic burden; incremental burden; HEALTH-CARE EXPENDITURES; SYMPTOM QUALITY; DIZZY PATIENTS; US ADULTS; DISORDERS; COSTS; EPIDEMIOLOGY; BALANCE; IMPACT;
D O I
10.3233/VES-201531
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
BACKGROUND: Vertigo and dizziness are extremely common conditions in the adult population and therefore place a significant social and economic burden on both patients and the healthcare system. However, limited information is available for the economic burden of vertigo and dizziness across various health care settings. OBJECTIVE: Estimate the economic burden of vertigo and dizziness, controlling for demographic, socioeconomic, and clinical comorbidities. METHODS: A retrospective analysis of data from the Medical Expenditures Panel Survey (2007-2015) was performed to analyze individuals with vertigo or dizziness from a nationally representative sample of the United States. Participants were included via self-reported data and International Classification of Diseases, 9th Revision Clinical Modification codes. A cross-validated 2-component generalized linear model was utilized to assess vertigo and dizziness expenditures across demographic, socioeconomic and clinical characteristics while controlling for covariates. Costs and utilization across various health care service sectors, including inpatient, outpatient, emergency department, home health, and prescription medications were evaluated. RESULTS: Of 221,273 patients over 18 years, 5,275 (66% female, 34% male) reported either vertigo or dizziness during 2007-2015. More patients with vertigo or dizziness were female, older, non-Hispanic Caucasian, publicly insured, and had significant clinical comorbidities compared to patients without either condition. Furthermore, each of these demographic, socioeconomic, and clinical characteristics lead to significantly elevated costs due to having these conditions for patients. Significantly higher medical expenditures and utilization across various healthcare sectors were associated with vertigo or dizziness (p < 0.001). The mean incremental annual healthcare expenditure directly associated with vertigo or dizziness was $2,658.73 (95% CI: 1868.79, 3385.66) after controlling for socioeconomic and demographic characteristics. Total annual medical expenditures for patients with dizziness or vertigo was $48.1 billion. CONCLUSION: Vertigo and dizziness lead to substantial expenses for patients across various healthcare settings. Determining how to limit costs and improve the delivery of care for these patients is of the utmost importance given the severe morbidity, disruption to daily living, and major socioeconomic burden associated with these conditions.
引用
收藏
页码:81 / 90
页数:10
相关论文
共 50 条
  • [41] ECONOMIC AND HUMANISTIC BURDEN OF HEPATOCELLULAR CARCINOMA IN THE UNITED STATES
    Kohn, C. G.
    Miller, J. D.
    Sill, B.
    Korytowsky, B.
    Parikh, N.
    Singh, P.
    VALUE IN HEALTH, 2017, 20 (05) : A101 - A101
  • [42] Economic Burden of Psoriasis in the United States A Systematic Review
    Brezinski, Elizabeth A.
    Dhillon, Jaskaran S.
    Armstrong, April W.
    JAMA DERMATOLOGY, 2015, 151 (06) : 651 - 658
  • [43] The Clinical and Economic Burden of Norovirus Gastroenteritis in the United States
    Bartsch, Sarah M.
    O'Shea, Kelly J.
    Lee, Bruce Y.
    JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (11): : 1910 - 1919
  • [44] Economic Burden of Legionnaires' Disease, United States, 2014
    Baker-Goering, Madeleine
    Roy, Kakoli
    Edens, Chris
    Collier, Sarah
    EMERGING INFECTIOUS DISEASES, 2021, 27 (01) : 255 - 257
  • [45] THE ECONOMIC BURDEN OF SICKLE CELL DISEASE IN THE UNITED STATES
    Huo, J.
    Xiao, H.
    Garg, M.
    Shah, C.
    Wilkie, D. J.
    Mainous, A., III
    VALUE IN HEALTH, 2018, 21 : S108 - S108
  • [46] The economic burden of chronic lymphocytic leukemia in the United States
    Morlock, R. J.
    Atkinson, M. J.
    Pollock, M. R.
    Matthies, A.
    VALUE IN HEALTH, 2008, 11 (03) : A66 - A66
  • [47] The Economic Burden of Vision Loss and Blindness in the United States
    Rein, David B.
    Wittenborn, John S.
    Zhang, Ping
    Sublett, Farah
    Lamuda, Phoebe A.
    Lundeen, Elizabeth A.
    Saaddine, Jinan
    OPHTHALMOLOGY, 2022, 129 (04) : 369 - 378
  • [48] The Economic Burden of Obesity by Glycemic Stage in the United States
    Li, Qian
    Blume, Steven W.
    Huang, Joanna C.
    Hammer, Mette
    Graf, Thomas R.
    PHARMACOECONOMICS, 2015, 33 (07) : 735 - 748
  • [49] THE ECONOMIC AND HUMANISTIC BURDEN OF GLIOMA IN THE UNITED STATES AND CANADA
    Pohlmann, J.
    Grabe-Heyne, K.
    Krott-Coi, L. M.
    Rabar, S.
    Pollock, R.
    VALUE IN HEALTH, 2024, 27 (06) : S223 - S223
  • [50] The Economic Burden of Graft Failure in the United States.
    Sussell, J. A.
    Silverstein, A. R.
    Goutam, P.
    Incerti, D.
    Kee, R.
    Batty, D. S., Jr.
    Chen, C. X.
    Jansen, J.
    Kasiske, B. L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 495 - 496